A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics

Kumthekar, P. U., Avram, M. J., Lassman, A. B., Lin, N. U., Lee, E., Grimm, S. A., Schwartz, M., Bell Burdett, K. L., Lukas, R. V., Dixit, K., Perron, I., Zhang, H., Gradishar, W. J., Pentsova, E. I., Jeyapalan, S., Groves, M. D., Melisko, M., & Raizer, J. J. (2022). A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-Oncology, 25(3), 557–565. https://doi.org/10.1093/neuonc/noac195
Authors:
Priya U Kumthekar
Michael J Avram
Andrew B Lassman
Nancy U Lin
Eudocia Lee
Sean A Grimm
Margaret Schwartz
Kirsten L Bell Burdett
Rimas V Lukas
Karan Dixit
Isabella Perron
Hui Zhang
William J Gradishar
Elena I Pentsova
Suriya Jeyapalan
Morris D Groves
Michelle Melisko
Jeffrey J Raizer
Affiliated Authors:
Andrew B Lassman
Subjects:
Author Keywords:
cns metastases
her2-positive metastases
leptomeningeal disease
Publication Type:
Article
Unique ID:
10.1093/neuonc/noac195
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: